NextPharma to acquire two sites of Lonza.

NextPharma, a European pharmaceutical Contract Development and Manufacturing Organisation, agreed to acquire two sites of Lonza, a Swiss multinational chemicals and biotechnology company. Financial terms were not disclosed. "At NextPharma, we are very excited at the prospect of adding two new centers of excellence, at Ploermel and Edinburgh, to our manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers. These technologies, combined with the know-how and expertise of the employees at both sites, would provide additional solutions for drug formulations which will benefit patients across the world. On behalf of NextPharma, I look forward to welcoming our future colleagues, and I am confident that together we will continue to further develop and grow NextPharma as a leading and wellrespected European CDMO," Peter Burema, NextPharma CEO.